Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead put profit ahead of hepatitis C patients -U.S. Senate report

[Reuters] – U.S. state Medicaid programs spent $1.3 billion before rebates in 2014 on Gilead Sciences’ new hepatitis C drugs to treat fewer than 2.4 percent of enrollees with the liver disease, according . . . → Read More: Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead put profit ahead of hepatitis C patients -U.S. Senate report Similar Articles: Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Sciences Announces Fourth Quarter 2015 Dividend Company Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Sciences to Release Third Quarter 2015 Financial Results on Tuesday, October 27, 2015 Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead combo drug fights all genotypes of hep C infection: data